Last reviewed · How we verify
NCT06069232: ARISTOTLE
Aortic Valve Diseases RISk facTOr assessmenT and Prognosis modeL Construction
trial in Aortic Valve Disease in 2,000 participants. Currently enrolling.
1 March 2028
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 March 2021 |
| Primary completion | 1 March 2028 |
| Estimated completion | 1 March 2028 |
| Sites | 7 locations across China |
Conditions studied
- Aortic Valve Disease — all drugs for Aortic Valve Disease →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 100, any sex, with Aortic Valve Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter cohort study including patients diagnosed with aortic valve disease during hospitalization, including aortic insufficiency and aortic valve stenosis. The primary outcome of the study was all-cause death, and the secondary outcome was cardiovascular events. Through follow-up observation, the prognostic risk factors of patients with aortic disease were evaluated, and a prognostic model was constructed to guide clinical decision-making.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Association between triglyceride-glucose-body mass index and risk of aortic stenosis progression in patients with non-severe aortic stenosis: a retrospective cohort study.
Guo Z, Xiong Z, He L, Zhang S, et al · · 2025 · cited 4× · PMID 39881345 · DOI 10.1186/s12933-025-02579-x -
Association Between the Malnutrition Status and All-Cause Mortality in Patients With Moderate and Severe Aortic Stenosis: A Prospective Cohort Study.
Li B, Zhang S, Xu C, Huang M, et al · · 2025 · cited 3× · PMID 39895526 · DOI 10.1161/jaha.124.037086 -
Association between cholesterol, high-density lipoprotein, and glucose index and risks of cardiovascular and all-cause mortality in patients with calcific aortic valve stenosis: the ARISTOTLE cohort study.
Guo Z, Xiong Z, Zhang W, Chen G, et al · · 2025 · cited 2× · PMID 41076530 · DOI 10.1186/s12933-025-02906-2 -
Evaluation of EuroSCORE II to Determine the Prognosis of Patients With Moderate-To-Severe Aortic Stenosis: A Long-Term Retrospective Study.
Cai X, Hu D, Yan B, Chen J, et al · · 2026 · PMID 41789337 · DOI 10.31083/rcm42757 -
Biological Age Acceleration and All-Cause Mortality in Moderate to Severe Aortic Valve Stenosis: A Prospective Cohort Study.
Zheng Y, Xu X, Xiong Z, Li B, et al · · 2026 · PMID 41618949 · DOI 10.1016/j.jacasi.2025.11.019
Verify or expand the search:
- PubMed search for NCT06069232
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Aortic Valve Disease
Currently open trials in the same condition.
- NCT07008911 — CardioHeartConnect: Commercially Available Fitness for Cardiac Rehabilitation · NA · recruiting
- NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
- NCT07021612 — A Clinical and Imaging Registry of Transcatheter Aortic Valve Implantation Using JenaValve System/ J-Valve System for Pa · recruiting
- NCT06896227 — TAVR: The Impact of Prothesis Positioning on Valvular and Coronary Hemodynamics · NA · recruiting
- NCT06189976 — Rapid Atrial Pacing After TAVI to Predict Pacemaker Implantation · NA · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06069232 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 12 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06069232.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing